Acticor Biotech
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
ALACT | PA
Overview
Corporate Details
- ISIN(s):
- FR0012519668 (+1 more)
- LEI:
- 969500K433EK1G89EV95
- Country:
- France
- Address:
- 82 AVENUE DU MAINE, 75014 PARIS
- Website:
- https://www.acticor-biotech.com
- Sector:
- Manufacturing
Description
Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-06 08:00 |
Inside Information / Other news releases
|
English | 171.0 KB | ||
| 2025-01-06 08:00 |
Informations privilégiées / Autres communiqués
|
French | 169.3 KB | ||
| 2024-12-19 18:00 |
Informations privilégiées / Autres communiqués
|
French | 205.7 KB | ||
| 2024-12-19 18:00 |
Inside Information / Other news releases
|
English | 214.6 KB | ||
| 2024-12-10 18:00 |
Informations privilégiées / Autres communiqués
|
French | 202.1 KB | ||
| 2024-12-10 18:00 |
Inside Information / Other news releases
|
English | 214.1 KB | ||
| 2024-11-06 08:30 |
Inside Information / Other news releases
|
English | 177.1 KB | ||
| 2024-11-06 08:30 |
Informations privilégiées / Autres communiqués
|
French | 179.2 KB | ||
| 2024-11-04 11:46 |
Inside Information / News release on accounts, results
|
English | 322.8 KB | ||
| 2024-11-04 11:46 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 311.2 KB | ||
| 2024-10-31 17:45 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 400.7 KB | ||
| 2024-10-31 17:45 |
Inside Information / News release on accounts, results
|
English | 464.4 KB | ||
| 2024-10-16 17:45 |
Inside Information / Other news releases
|
English | 289.1 KB | ||
| 2024-10-16 17:45 |
Informations privilégiées / Autres communiqués
|
French | 223.1 KB | ||
| 2024-10-14 08:00 |
Informations privilégiées / Autres communiqués
|
French | 275.7 KB |
Automate Your Workflow. Get a real-time feed of all Acticor Biotech filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Acticor Biotech
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Acticor Biotech via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
